jRCT2031240211招募中不适用
Phase III study to evaluate the efficacy and safety of TH-004 in patients with postherpetic neuralgia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 160
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •(1) Japanese patients aged 18 years or older at the time of informed consent.
- •(2) Patients diagnosed with postherpetic neuralgia (PHN) who continue to have pain at least 3 months after the onset of herpes zoster at the time of informed consent.
- •(3) closed to the public (NRS score).
- •(4) Patients who are able to comply with the rules during clinical trial participation, undergo examinations and tests prescribed in the clinical trial procedures, report subjective symptoms, etc., and respond appropriately to the patient diary.
- •(5) Patients who are fully informed about and understand the purpose and content of the clinical trial, expected drug efficacy, pharmacological effects, and risks and who have given voluntary written consent.
排除标准
- •(1) closed to the public (NRS score).
- •(2) Patients who underwent nerve block surgery for PHN (Nerve destruction with chemicals using phenol and ethanol, high-frequency thermocoagulation, etc.) or who have undergone pulse radiofrequency, etc. within 30 days before the start of the screening period. Patients who underwent nerve block surgery, etc. that does not involve nerve destruction.
- •(3) Patients who used strong opioid analgesics within 30 days before the start of the screening period.
- •(4) Patients who have had a change in the dosage and administration of drugs with analgesic action (including prescriptions for analgesia) for PHN or neuropathic pain, such as antidepressants, antiepileptics, anxiolytics, antipsychotics, N-methyl-D-aspartate (NMDA) receptor antagonists, corticosteroids, alpha-2-adrenoceptor agonists, NSAIDs, acetaminophen, weak opioids, and Chinese medicines since 2 weeks before the start of the screening period, or patients who are judged to have an impact on the analgesic effect of TH-004 on PHN (excluding topical agents intended for local action).
- •(5) Patients with other pain not related to PHN at the beginning of the screening period that may affect the assessment of PHN.
- •(6) Patients with skin symptoms (eczema, ulcers, erosion, etc.) at the PHN site that may affect the assessment of pain or safety.
- •(7) Patients with cardiac conduction disorders.
- •(8) Patients who have previously been treated with topical lidocaine and judged ineffective for PHN.
- •(9) Patients with hypersensitivity to amide-type local anesthetics, including lidocaine.
- •(10) Patients who had complications and/or a history of cardiovascular disease, hepatic disease, renal disease, endocrine disease, gastrointestinal disease, hematologic disease, respiratory disease, or central/neuropsychiatric disease within 12 months before the start of the screening period, and patients who were judged inappropriate by the investigator (sub investigator).
- •(11) For non-menopausal women, patients with a positive pregnancy test at screening or those who are breastfeeding.
- •(12) For women of childbearing potential, or for men with a childbearing partner, who cannot consent to abstinence or the use of effective contraception as part of their lifestyle from the time of informed consent until 28 days after the last dose of study drug.
- •(13) Patients who are currently participating in another study or who have participated in another study within 30 days of obtaining informed consent.
- •(14) Other patients judged by the investigator (sub investigator) to be unsuitable for the study.
结局指标
主要结局
-
Efficacy: Analgesic response during the double-blind phase
次要结局
未报告次要终点
研究者
相似试验
已完成
3 期
Phase III study of FTB-8127 in patients with post-herpetic neuralgia (A placebo-controlled, multicenter, double-blind, parallel-group study)Post-herpetic neuralgiaJPRN-jRCT2080220444FUSO Pharmaceutical Industries, Ltd.135
进行中（未招募）
不适用
A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy - NDTreatment of Chronic Myeloid LeukemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2006-006881-40-ITERVIANO MEDICAL SCIENCES16
尚未招募
3 期
A Clinical Study of rhPTH (1-84) Treatment in Japanese Participants With Chronic HypoparathyroidismChronic HypoparathyroidismJPRN-jRCT2080224751Takeda Pharmaceutical Company Limited12
未知
2 期
Phase 2/3 clinical study of HP-3150 in patients with cancer pain.Cancer painJPRN-jRCT2080222905Hisamitsu Pharmaceutical Co., Inc
未知
3 期
Z-103 Phase III Clinical Study in patients with Taste Disorder - A placebo-controlled superiority studytaste disorders induced by zinc-deficiencyJPRN-jRCT2080221862Zeria Pharmaceutical Co., Ltd.260